NCT00003495 - Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 27, 1996

Primary Completion Date

November 4, 2003

Study Completion Date

November 4, 2003

Conditions

Stage IV Lung Cancer

Interventions

DRUG

Antineoplaston therapy (Atengenal + Astugenal)

"Patients with Stage IV or Recurrent Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston